Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer

A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival

(2014) Shahzia Anjum et al.   Genome Medicine

Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy

(2013) Y. Xu et al.   ANNALS OF ONCOLOGY

Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

(2013) Rachel Greenup et al.   ANNALS OF SURGICAL ONCOLOGY

BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC

(2013) T. Ignatov et al.   BREAST CANCER RESEARCH AND TREATMENT

PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer

(2013) Mohammad R. Akbari et al.   JNCI-Journal of the National Cancer Institute

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

(2012) N. Mavaddat et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

BRCA1epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

(2012) Olafur A. Stefansson et al.   Epigenetics

Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer

(2012) T. Hansmann et al.   HUMAN MOLECULAR GENETICS

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

(2012) Elise Ruark et al.   NATURE

Higher population-based incidence rates of triple-negative breast cancer among young African-American women

(2011) Kathryn C. Amirikia et al.   CANCER

Triple-negative breast cancer in Hispanic patients

(2011) Fernando Lara-Medina et al.   CANCER

Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events

(2011) Tomasz K Wojdacz et al.   Diagnostic Pathology

No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls

(2011) Tomasz K Wojdacz et al.   Future Oncology

BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation

(2010) Takashi Iwamoto et al.   BREAST CANCER RESEARCH AND TREATMENT

Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer

(2010) E. M. Wong et al.   Cancer Prevention Research

BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors

(2010) Jurgen Veeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Methylation not a frequent “second hit” in tumors with germline BRCA mutations

(2009) Amy M. Dworkin et al.   Familial Cancer

Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers

(2008) Tair Kontorovich et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY